Lipocine Inc公布了其研究药物LPCN 1154针对产后抑郁症患者所取得的主要安全性与有效性试验结果。该数据揭示了该疗法在此患者群体中的表现,为后续研发提供了关键依据。
Lipocine Inc公布了其研究药物LPCN 1154针对产后抑郁症患者所取得的主要安全性与有效性试验结果。该数据揭示了该疗法在此患者群体中的表现,为后续研发提供了关键依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.